Charles Schwab’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $127M | Buy |
1,605,054
+21,788
| +1% | +$1.64M | 0.02% | 649 |
|
|
2026
Q1 | $119M | Buy |
1,583,266
+41,425
| +3% | +$3.27M | 0.02% | 642 |
|
|
2025
Q4 | $122M | Buy |
1,541,841
+21,890
| +1% | +$1.65M | 0.02% | 627 |
|
|
2025
Q3 | $99.4M | Buy |
1,519,951
+32,133
| +2% | +$1.57M | 0.02% | 719 |
|
|
2025
Q2 | $58.8M | Buy |
1,487,818
+44,189
| +3% | +$1.45M | 0.01% | 1000 |
|
|
2025
Q1 | $43.6M | Sell |
1,443,629
-37,811
| -3% | -$1.24M | 0.01% | 1169 |
|
|
2024
Q4 | $51.8M | Buy |
1,481,440
+38,420
| +3% | +$1.44M | 0.01% | 1108 |
|
|
2024
Q3 | $57.8M | Buy |
1,443,020
+114,914
| +9% | +$5.35M | 0.01% | 1025 |
|
|
2024
Q2 | $63.3M | Buy |
1,328,106
+26,738
| +2% | +$1.1M | 0.01% | 897 |
|
|
2024
Q1 | $56.4M | Buy |
1,301,368
+26,049
| +2% | +$1.24M | 0.01% | 955 |
|
|
2023
Q4 | $64.5M | Buy |
1,275,319
+33,012
| +3% | +$1.58M | 0.02% | 801 |
|
|
2023
Q3 | $56.4M | Buy |
1,242,307
+43,087
| +4% | +$1.78M | 0.02% | 802 |
|
|
2023
Q2 | $49.2M | Buy |
1,199,220
+12,827
| +1% | +$493K | 0.01% | 870 |
|
|
2023
Q1 | $42.4M | Sell |
1,186,393
-69,875
| -6% | -$2.62M | 0.01% | 950 |
|
|
2022
Q4 | $47.4M | Buy |
1,256,268
+53,922
| +4% | +$2.27M | 0.02% | 855 |
|
|
2022
Q3 | $53.2M | Buy |
1,202,346
+48,321
| +4% | +$2.04M | 0.02% | 719 |
|
|
2022
Q2 | $42.7M | Buy |
1,154,025
+16,198
| +1% | +$611K | 0.01% | 849 |
|
|
2022
Q1 | $42.1M | Buy |
1,137,827
+44,388
| +4% | +$1.45M | 0.01% | 985 |
|
|
2021
Q4 | $33.3M | Buy |
1,093,439
+23,707
| +2% | +$746K | 0.01% | 1193 |
|
|
2021
Q3 | $35.9M | Buy |
1,069,732
+355,772
| +50% | +$13.4M | 0.01% | 1092 |
|
|
2021
Q2 | $28.5M | Buy |
713,960
+17,464
| +3% | +$684K | 0.01% | 1291 |
|
|
2021
Q1 | $31.3M | Buy |
696,496
+5,087
| +0.7% | +$284K | 0.01% | 1157 |
|
|
2020
Q4 | $39.1M | Buy |
691,409
+10,205
| +1% | +$509K | 0.02% | 936 |
|
|
2020
Q3 | $32.3M | Buy |
681,204
+64,735
| +11% | +$3.6M | 0.01% | 905 |
|
|
2020
Q2 | $36.3M | Buy |
616,469
+5,770
| +0.9% | +$321K | 0.02% | 772 |
|
|
2020
Q1 | $28.9M | Buy |
610,699
+13,474
| +2% | +$751K | 0.02% | 767 |
|
|
2019
Q4 | $36.1M | Buy |
597,225
+9,126
| +2% | +$544K | 0.02% | 827 |
|
|
2019
Q3 | $35.2M | Sell |
588,099
-28,414
| -5% | -$1.85M | 0.02% | 786 |
|
|
2019
Q2 | $39.6M | Buy |
616,513
+33,997
| +6% | +$2.4M | 0.02% | 690 |
|
|
2019
Q1 | $47.3M | Buy |
582,516
+37,679
| +7% | +$2.43M | 0.03% | 568 |
|
|
2018
Q4 | $29.5M | Buy |
544,837
+19,082
| +4% | +$973K | 0.02% | 730 |
|
|
2018
Q3 | $27.1M | Buy |
525,755
+71,526
| +16% | +$3.36M | 0.02% | 939 |
|
|
2018
Q2 | $18.9M | Buy |
454,229
+27,355
| +6% | +$1.21M | 0.01% | 1130 |
|
|
2018
Q1 | $18.8M | Buy |
426,874
+24,894
| +6% | +$1.26M | 0.01% | 1046 |
|
|
2017
Q4 | $20.2M | Buy |
401,980
+20,246
| +5% | +$1.11M | 0.02% | 972 |
|
|
2017
Q3 | $19.4M | Buy |
381,734
+14,184
| +4% | +$743K | 0.02% | 950 |
|
|
2017
Q2 | $18.7M | Buy |
367,550
+54,587
| +17% | +$2.54M | 0.02% | 895 |
|
|
2017
Q1 | $12.6M | Buy |
312,963
+3,688
| +1% | +$166K | 0.01% | 1144 |
|
|
2016
Q4 | $14.8M | Buy |
309,275
+39,145
| +14% | +$1.55M | 0.02% | 967 |
|
|
2016
Q3 | $9.9M | Buy |
270,130
+62,194
| +30% | +$1.95M | 0.01% | 1170 |
|
|
2016
Q2 | $4.84M | Sell |
207,936
-52,929
| -20% | -$1.71M | 0.01% | 1578 |
|
|
2016
Q1 | $10.6M | Buy |
260,865
+4,895
| +2% | +$199K | 0.01% | 1014 |
|
|
2015
Q4 | $15.9M | Buy |
255,970
+21,139
| +9% | +$1.14M | 0.02% | 712 |
|
|
2015
Q3 | $9.49M | Buy |
234,831
+16,946
| +8% | +$877K | 0.01% | 1031 |
|
|
2015
Q2 | $12.5M | Sell |
217,885
-161,645
| -43% | -$10.3M | 0.02% | 865 |
|
|
2015
Q1 | $24.2M | Buy |
379,530
+20,294
| +6% | +$1.38M | 0.03% | 489 |
|
|
2014
Q4 | $22.2M | Buy |
359,236
+9,077
| +3% | +$448K | 0.03% | 493 |
|
|
2014
Q3 | $13.6M | Buy |
350,159
+5,700
| +2% | +$202K | 0.02% | 629 |
|
|
2014
Q2 | $11.9M | Buy |
344,459
+3,282
| +1% | +$103K | 0.02% | 699 |
|
|
2014
Q1 | $14.7M | Sell |
341,177
-12,685
| -4% | -$615K | 0.03% | 571 |
|
|
2013
Q4 | $14.1M | Buy |
353,862
+64,821
| +22% | +$2.31M | 0.03% | 543 |
|
|
2013
Q3 | $11M | Sell |
289,041
-122,559
| -30% | -$3.66M | 0.02% | 599 |
|
|
2013
Q2 | $11.7M | Buy |
+411,600
| New | +$8.75M | 0.03% | 514 |
|
Other funds holding IONS
Charles Schwab's IONS Position: Q2 2026 in Review
Charles Schwab increased its Ionis Pharmaceuticals (IONS) stake by 1.4% in Q2 2026, buying an estimated $1.64M and bringing the position to 1,605,054 shares worth $127M. The position accounts for 0.02% of the portfolio, ranked #649.
Charles Schwab first reported a position in IONS in Q2 2013 and has held it in 53 quarters since. 511 funds tracked by Wall St. Rank hold IONS as of Q2 2026.
- Charles Schwab held 1,605,054 shares of Ionis Pharmaceuticals worth $127M as of Q2 2026.
- Charles Schwab bought 21,788 Ionis Pharmaceuticals shares in Q2 2026, an estimated $1.64M.
- Ionis Pharmaceuticals made up 0.02% of Charles Schwab's portfolio in Q2 2026, its #649 holding.
- Charles Schwab first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- 511 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.